News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck KGaA Expects MS Pill to Lift Drugs Margin
June 30, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- German pharmaceuticals and chemicals company Merck KGaA is banking on an experimental multiple sclerosis (MS) pill to lift operating margins at its embattled drugs unit, it said on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Approvals
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
November 19, 2026
·
3 min read
·
Heather McKenzie
Insights
The untapped potential of drug repurposing
November 19, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Approvals
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
November 18, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
November 18, 2026
·
3 min read
·
Annalee Armstrong